Equities Analysts Offer Predictions for INTS Q2 Earnings

Posted by on May 15th, 2026

Intensity Therapeutics Inc. (NASDAQ:INTS – Free Report) – Investment analysts at Brookline Capital Markets increased their Q2 2026 EPS estimates for shares of Intensity Therapeutics in a research note issued on Wednesday, May 13th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings of ($0.81) per share for the quarter, up from their prior forecast of ($1.06). The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($3.46) per share. Brookline Capital Markets also issued estimates for Intensity Therapeutics’ Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.70) EPS, FY2027 earnings at ($1.90) EPS and FY2028 earnings at ($5.12) EPS.

Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.12.

Other equities research analysts also recently issued reports about the company. Weiss Ratings cut shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. Wall Street Zen raised shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Finally, Freedom Capital upgraded shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Intensity Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

View Our Latest Research Report on INTS

Intensity Therapeutics Trading Up 2.7%

Shares of INTS opened at $4.90 on Friday. Intensity Therapeutics has a 1 year low of $4.63 and a 1 year high of $43.50. The company has a 50 day simple moving average of $5.86 and a two-hundred day simple moving average of $8.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.86 and a quick ratio of 4.86. The firm has a market cap of $13.24 million, a P/E ratio of -0.86 and a beta of 2.94.

Institutional Trading of Intensity Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in Intensity Therapeutics by 77.8% during the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after buying an additional 201,357 shares in the last quarter. Legacy Advisors LLC bought a new position in Intensity Therapeutics in the 4th quarter worth about $63,000. Mesirow Financial Investment Management Inc. increased its position in shares of Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after acquiring an additional 51,000 shares during the period. Jane Street Group LLC bought a new stake in shares of Intensity Therapeutics during the fourth quarter valued at approximately $26,000. Finally, State Street Corp raised its stake in shares of Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after acquiring an additional 121,700 shares in the last quarter. Hedge funds and other institutional investors own 3.74% of the company’s stock.

About Intensity Therapeutics

(Get Free Report)

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.

Featured Stories

Earnings History and Estimates for Intensity Therapeutics (NASDAQ:INTS)

Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.